Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunocore Holdings Plc ADR (IMCR)

Immunocore Holdings Plc ADR (IMCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,621,703
  • Shares Outstanding, K 50,068
  • Annual Sales, $ 310,200 K
  • Annual Income, $ -51,090 K
  • EBIT $ -48 M
  • EBITDA $ -43 M
  • 60-Month Beta 0.75
  • Price/Sales 5.00
  • Price/Cash Flow N/A
  • Price/Book 4.10

Options Overview Details

View History
  • Implied Volatility 54.63% ( -1.72%)
  • Historical Volatility 50.92%
  • IV Percentile 7%
  • IV Rank 12.99%
  • IV High 109.35% on 05/22/24
  • IV Low 46.46% on 05/19/25
  • Put/Call Vol Ratio 0.01
  • Today's Volume 307
  • Volume Avg (30-Day) 353
  • Put/Call OI Ratio 3.78
  • Today's Open Interest 13,177
  • Open Int (30-Day) 11,140

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.24
  • Number of Estimates 7
  • High Estimate -0.04
  • Low Estimate -0.51
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.44 +15.38%
on 05/15/25
32.99 -4.03%
on 05/21/25
+2.25 (+7.65%)
since 04/21/25
3-Month
23.15 +36.76%
on 04/09/25
32.99 -4.03%
on 05/21/25
+1.74 (+5.82%)
since 02/21/25
52-Week
23.15 +36.76%
on 04/09/25
51.50 -38.52%
on 05/22/24
-19.34 (-37.92%)
since 05/21/24

Most Recent Stories

More News
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates

Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss...

IMCR : 31.66 (-2.25%)
PBYI : 3.35 (-7.71%)
ADMA : 20.12 (-1.57%)
ANIP : 59.08 (-2.57%)
New Strong Buy Stocks for May 8th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:BrightSpring Health Services, Inc. BTSG: This home and community-based healthcare services platform has seen the Zacks Consensus...

IMCR : 31.66 (-2.25%)
UBSI : 36.06 (-3.01%)
BTSG : 23.74 (-0.34%)
MNRO : 12.37 (-9.84%)
NWFL : 25.68 (-1.93%)
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion Therapeutics ESPR incurred a loss of 21 cents per share in the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, Esperion...

ESPR : 0.8530 (-6.13%)
IMCR : 31.66 (-2.25%)
ANIP : 59.08 (-2.57%)
NTLA : 9.20 (-4.86%)
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates

Beam Therapeutics BEAM reported a loss of $1.24 per share for the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of $1.11. The company had reported a loss of $1.21 per...

BEAM : 17.22 (-2.99%)
IMCR : 31.66 (-2.25%)
ANIP : 59.08 (-2.57%)
NTLA : 9.20 (-4.86%)
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome Therapeutics AXSM incurred an adjusted loss of $1.22 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.26. The company had incurred a loss of $1.44...

IMCR : 31.66 (-2.25%)
JAZZ : 108.27 (-2.48%)
ADMA : 20.12 (-1.57%)
AXSM : 105.76 (-2.39%)
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates

Alkermes plc ALKS reported earnings from continuing operations of 13 cents per share for first-quarter 2025, which missed the Zacks Consensus Estimate of 28 cents. The company had reported earnings of...

BEAM : 17.22 (-2.99%)
IMCR : 31.66 (-2.25%)
ADMA : 20.12 (-1.57%)
ALKS : 30.53 (-3.60%)
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates

Agios Pharmaceuticals AGIO incurred a loss of $1.55 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.80. In the year-ago quarter, the company had reported...

BEAM : 17.22 (-2.99%)
IMCR : 31.66 (-2.25%)
AGIO : 30.11 (-0.20%)
ADMA : 20.12 (-1.57%)
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y

Repligen Corporation RGEN reported first-quarter 2025 adjusted earnings per share of 39 cents, which beat the Zacks Consensus Estimate of 35 cents. The company had recorded adjusted earnings of 30 cents...

BEAM : 17.22 (-2.99%)
IMCR : 31.66 (-2.25%)
RGEN : 120.21 (-5.78%)
ADMA : 20.12 (-1.57%)
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates

Puma Biotechnology PBYI reported fourth-quarter 2024 adjusted earnings of 43 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company reported adjusted...

FOLD : 6.34 (-3.79%)
IMCR : 31.66 (-2.25%)
PBYI : 3.35 (-7.71%)
PCRX : 26.14 (-2.28%)
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales

Shares of Bausch Health Companies Inc. BHC gained 2.36% after the company reported better-than-expected fourth-quarter results. Shares also gained 7.8% in aftermarket trading.Adjusted earnings per share...

IMCR : 31.66 (-2.25%)
PCRX : 26.14 (-2.28%)
BHC : 4.48 (-4.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 34.72
2nd Resistance Point 33.85
1st Resistance Point 32.76
Last Price 31.66
1st Support Level 30.80
2nd Support Level 29.93
3rd Support Level 28.84

See More

52-Week High 51.50
Fibonacci 61.8% 40.67
Fibonacci 50% 37.33
Fibonacci 38.2% 33.98
Last Price 31.66
52-Week Low 23.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar